Navigation Links
Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
Date:10/31/2013

AUSTIN, Texas, Oct. 31, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 14, 2013, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2013. Financial results will be issued in a press release prior to the call.

Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.

Date: Thursday, November 14, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-734-8507
International dial-in number: 1-212- 231-2918
Conference ID: 21676489       
Webcast: http://www.media-server.com/m/p/kb996t2n

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through November 28, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21676489

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart guided journaling tool ... on the current state of anxiety in support of National Mental Health Awareness Month. ... April 2017 and benchmarked general anxiety levels as well as identified the top triggers, ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... now welcoming new patients with periodontal plastic surgery treatments, including crown lengthening ... dentist. Dr. Green provides these esthetic and functional procedures to help patients improve ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less than ... when it was targeted to build a nuclear plant by the TOSHIBA Corporation. , ... Marvin L. Yoder describes the journey to get power to his small town, off ...
(Date:5/21/2017)... ... ... 52, was found dead on the night of Wednesday, May 17, 2017. It can be ... rock industry would take his own life, but the extremely talented and admired singer ... role in the death of Chris Cornell . , Depression and Drug Use , ...
(Date:5/21/2017)... PARK, FL (PRWEB) , ... May 20, 2017 , ... ... sell it, find it, review it, and share its attributes like never before. More ... dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for the ...
Breaking Medicine News(10 mins):